article thumbnail

STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves


Patents on big-selling medicines expire, but new medicines will come to take their place. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. ” Basically, the tide comes in, but it also goes out.